olfactory receptor family 2 subfamily AT member 2 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR2AT2P profile across patient tissues and cancer cell-line models. OR2AT2P expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, OR2AT2P is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, OR2AT2P RNA expression shows 5,963 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, KIRC, and STAD as cancer lineages where OR2AT2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR2AT2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR2AT2P survival associations across molecular data types. OR2AT2P RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR2AT2P RNA expression–survival associations across cancer types. High OR2AT2P expression shows unfavorable associations in UCEC, ESCA, UVM, STAD and LGG, but favorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify LUAD as the clearest survival context for OR2AT2P RNA expression.
This table summarizes OR2AT2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR2AT2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR2AT2P shows higher tumor expression in KIRC. The KIRC box plot shows higher OR2AT2P RNA expression in tumor versus normal tissue (log2 FC = +0.041, t-test p < 0.001).
This table shows molecular features associated with OR2AT2P in patient tissues and cancer cell lines. In patient samples, OR2AT2P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
